论文部分内容阅读
目的探讨结直肠癌组织乳腺癌易感基因1(BRCA1)表达与多西紫杉醇、奥沙利铂体外敏感性的关系。方法实时荧光定量PCR检测50例病理确诊的人结直肠癌组织中BRCA1mRNA表达。采用组织培养药敏法评估多西紫杉醇和奥沙利铂两种药物的体外敏感性。结果多西紫杉醇和奥沙利铂平均抑制率分别为34.91%和43.75%。25例多西紫杉醇敏感组织和25例多西紫杉醇耐药组织中BRCA1mRNA相对表达量相仿(6.19vs.4.27)(P>0.05)。25例奥沙利铂敏感组织BRCA1mRNA相对表达量低于25例奥沙利铂耐药组织(3.86vs.6.59)(P<0.05)。结论结直肠癌组织对奥沙利铂的敏感性与BRCA1mRNA表达水平呈负相关。
Objective To investigate the relationship between the expression of BRCA1 and the sensitivity of docetaxel and oxaliplatin in colorectal cancer. Methods Real-time fluorescent quantitative PCR was used to detect the expression of BRCA1 mRNA in 50 pathologically confirmed human colorectal cancer tissues. In vitro sensitivity of docetaxel and oxaliplatin was assessed by tissue culture susceptibility assay. Results The average inhibitory rates of docetaxel and oxaliplatin were 34.91% and 43.75%, respectively. The relative expression levels of BRCA1 mRNA in 25 docetaxel-sensitive tissues and 25 docetaxel-resistant tissues were similar (6.19 vs. 4.27) (P> 0.05). The relative expression of BRCA1 mRNA in 25 cases of oxaliplatin-sensitive tissues was lower than that of 25 cases of oxaliplatin-resistant tissues (3.86 vs.6.59) (P <0.05). Conclusion The sensitivity of colorectal cancer to oxaliplatin is negatively correlated with the expression of BRCA1 mRNA.